Drug Type Monoclonal antibody |
Synonyms- |
Target |
Action inhibitors |
Mechanism CD6 inhibitors(T-cell differentiation antigen CD6 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Multiple Sclerosis | Preclinical | United States | 20 Aug 2024 | |
| Non-Small Cell Lung Cancer | Preclinical | United States | 20 Aug 2024 | |
| Prostatic Cancer | Preclinical | United States | 20 Aug 2024 | |
| Rheumatoid Arthritis | Preclinical | United States | 20 Aug 2024 | |
| Triple Negative Breast Cancer | Preclinical | United States | 20 Aug 2024 | |
| Uveitis | Preclinical | United States | 20 Aug 2024 |






